Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics

Cited by (398)

Items 301–398 of 398

1. Studies of the Basic Pharmacokinetic Properties of a Drug—a Regulatory Perspective
   M. Sunzel · 2004
2. Cytochrome P450 in Laboratory Animal Species
   M. Spatzenegger, S. Born, J. Halpert · 2003
3. Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor
   R. Mullangi, P. Ahlawat, R. Trivedi, N. Srinivas · 2010 · European journal of drug metabolism and pharmacokinetics
4. The avian respiratory system: implications for anaesthesia
   J. Ludders · 2025 · Philosophical Transactions B
5. Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein
   Rami Ayoun Alsoud, Natacha Le Moan, Lars Holten-Andersen, Tom Knudsen, Hans Lennernäs, Ulrika S. H. Simonsson · 2024 · Journal of Pharmaceutical Sciences
6. Physiologically‐based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans
   Anjani Ganti, Sijia Yu, Danielle Sharpnack, Ellen Ingalla, Tom De Bruyn · 2023 · Biopharmaceutics & Drug Disposition
7. A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys
   Iftekhar Mahmood · 2022 · Antibodies
8. Allometric Optimization of Enrofloxacin Dosage in Growing Male Turkeys: Empirical Evidence for Improved Internal Exposure
   B. Poźniak, M. Tikhomirov, K. Motykiewicz-Pers, K. Bobrek, M. Świtała · 2020 · Antibiotics
9. Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice
   Philippe Bernard Pierrillas, Émilie Hénin, Julien R. Ogier, Laurence Kraus‐Berthier, Marylore Chenel, François Bouzom, Michel M. Tod · 2018 · Journal of Pharmacology and Experimental Therapeutics
10. Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles
    Nuggehally R. Srinivas, Ravi Kumar Jairam, Sadanand Rangnathrao Mallurwar, Suresh Ponnayyan Sulochana, Devaraj Venkatapura Chandrashekar, Ravi Kanth Bhamidipati, Wolfgang Richter, Ramesh Mullangi · 2018 · Drug Research
11. The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway
    Sherri A. Smith, Jennifer G. Hoyt, Nigel Whitebread, Joseph Manna, Marisa Peluso, Kerrie Faia, Veronica T. Campbell, Martin Tremblay, Somarajan J. Nair, Michael J. Grogan et al. · 2013 · Xenobiotica
12. Use of Animals for the Determination of Absorption and Bioavailability
    Chris Logan · 2008 · Methods and principles in medicinal chemistry
13. Prediction of Hepatic Clearance in Humans from Experimental Animals and In Vitro Data
    Masato Chiba, Yuichi Sugiyama, Yasuyuki Ishii, Hiroyuki Takahashi, Yoshihiro Shibata · 2003 · Informa Healthcare eBooks
14. Influence of Arterial vs. Venous Sampling Site on Nicotine Tolerance Model Selection and Parameter Estimation
    F. Schaedeli, M. Pitsiu, N. Benowitz, S. Gourlay, D. Verotta · 2002 · Journal of Pharmacokinetics and Pharmacodynamics
15. The use of toxicokinetics for the safety assessment of drugs acting in the brain
    D. Campbell · 1995 · Molecular Neurobiology
16. Chapter 18 – Anesthesia and Analgesia in Birds
    J. Ludders · 2008
17. Biodistribution of mRNA vaccines in rats: Enrichment in injection site and lymph tissues and rapid clearance without tissue persistence
    Susan M.G. Goody, Christopher Rowbottom, Yun Liu, Nancy Chen · 2026 · Molecular Therapy — Nucleic Acids
18. Metronidazole Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically-Based Pharmacokinetic Modeling
    Fatma Kir, W. J. Jusko · 2025 · AAPS Journal
19. Modeling and Simulation as a Tool to Assess Voriconazole Exposure in the Central Nervous System
    Keli Jaqueline Staudt, Bruna Bernar Dias, Izabel Almeida Alves, Bénédicte Lelièvre, Jean‐Philippe Bouchara, Bibiana Verlindo de Araújo · 2023 · Pharmaceutics
20. Is the 90-day dog study necessary for pesticide toxicity testing?
    P. Bishop, V. Dellarco, D. Wolf · 2023 · Critical Reviews in Toxicology
21. Pharmacokinetics of a long-acting subcutaneous eprinomectin injection in semi-domesticated reindeer (Rangifer tarandus tarandus) - A pilot study.
    R. Davidson, C. Fæste, S. Uhlig, Feng-Ling Tukun, Hans Lian, H. Solvang, Renate Thorvaldsen, L. Folkow, J. S. Romano, Marianne Vinje Kilvær et al. · 2022 · Environmental Toxicology and Pharmacology
22. Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles
    Ravi Kumar Jairam, Sadanand Rangnathrao Mallurwar, Suresh Ponnayyan Sulochana, Devaraj V. Chandrasekhar, Umesh Todmal, Ravi Kanth Bhamidipati, Wolfgang Richter, Nuggehally R. Srinivas, Ramesh Mullangi · 2019 · AAPS PharmSciTech
23. Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor
    Bianca M. Liederer, Jonathan Cheong, Kang-Jye Chou, Peter S. Dragovich, Hoa Thi Le, Xiaorong Liang, Justin Ly, Sophie Mukadam, Jason Oeh, Deepak Sampath et al. · 2018 · Xenobiotica
24. Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients.
    Yumiko Matsuo, T. Ishibashi, K. Shimamura, T. Wajima · 2015 · Journal of Pharmacy and Science
25. Vigabatrin pediatric dosing information for refractory complex partial seizures: Results from a population dose–response analysis
    J. Nielsen, D. Tolbert, M. Patel, K. Kowalski, D. Wesche · 2014 · Epilepsia
26. Allometric scaling and prediction of concentration-time profiles of coagulation factors in humans from animals
    I. Mahmood · 2013 · Xenobiotica; the fate of foreign compounds in biological systems
27. Prediction of drug concentration-time profiles of therapeutic proteins in humans from animals
    Iftekhar Mahmood · 2012 · Xenobiotica
28. Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach
    Ravindranath Reddy Gilibili, Ramesh Mullangi, Nuggehally R. Srinivas · 2011 · European Journal of Drug Metabolism and Pharmacokinetics
29. Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease.
    N. Tajima, S. Nagashima, T. Uematsu, H. Torii, Masami Tajima, A. Hishida, H. Naganuma · 2006 · Biological and Pharmaceutical Bulletin
30. Prediction of drug clearance in humans from laboratory animals based on body surface area
    X.-D. Liu, J. Chen · 2001 · European journal of drug metabolism and pharmacokinetics
31. Nonlinear Mixed Effects Modeling in Systems Pharmacology
    Peter L. Bonate, Amit V. Desai, Ahsan Rizwan, Lu Zheng, Stacey J. Tannenbaum · 2016 · AAPS advances in the pharmaceutical sciences series
32. Interspecies uncertainty in molecular responses and toxicity of mixtures.
    M. Mumtaz, H. Pohl · 2012 · Experientia. Supplementum
33. Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions
    Mallillin, Marlon C., Silva, Daniela A., Miller, Neil A., Zhao, Shengnan, Salami, Maryam, Löbenberg, Raimar, Davies, Neal M. · 2026 · Pharmaceutics
34. Effects of oral administration of botanical extracts of oak leaves (Quercus sideroxyla Bonpl.) obtained by infusion and supercritical fluids
    Saúl Alberto Álvarez, N. Rocha-Guzmán, M. Moreno-Jiménez, Alejo Macías-Salas, M. Romo-Vaquero, K. Herrera-Rocha, J. A. Mendiola, J. Gallegos-Infante, R. González-Laredo · 2025 · Food Research International
35. Controlled release of MT-1207 using a novel gastroretentive bilayer system comprised of hydrophilic and hydrophobic polymers
    Napoleon-Nikolaos Vrettos, Peng Wang, Yu-Han Wang, C. Roberts, Jin-Yi Xu, Hong Yao, Zhe-Ying Zhu · 2023 · Pharmaceutical development and technology (Print)
36. Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
    Xiaoqing Fan, Wojciech Krzyżański, Dongyang Liu, Raymond S. M. Wong, Xiaoyu Yan · 2023 · Pharmaceutics
37. The Scaling of Blood Pressure and Volume
    J. Chaui-Berlinck, J. E. Bicudo · 2021 · Foundations
38. Pharmacokinetics of Drug Metabolites
    Philip C. Smith · 2019 · Handbook of Drug Metabolism
39. Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?
    A. Taneja, A. Vermeulen, D. Huntjens, M. Danhof, E. de Lange, J. Proost · 2017 · Pharmacology Research & Perspectives
40. Calculation of a First-In-Man Dose of 7-O-Succinyl Macrolactin A Based on Allometric Scaling of Data from Mice, Rats, and Dogs
    Keumhan Noh, ψ Wonku Kang · 2017 · Biomolecules & Therapeutics
41. The Need for Human Exposure Projection in the Interpretation of PreclinicalIn VitroandIn VivoADME Tox Data
    Patrick Poulin · 2016 · Wiley eBooks
42. Pharmacokinetic scaling of epirubicin using allometric and species-invariant time methods
    D. Shin, S. Park, S. Jeong, Oh-Seung Kwon, Chun-Woong Park, Kun Han, Y. Chung · 2015 · Journal of Pharmaceutical Investigation
43. A New Phase of Drug Discovery? The Rise of Pk/Pd Means Extremely Challenging Work at The Coalface
    Dennis A. Smith · 2015 · Bioanalysis
44. Hypothesis Generation and Pharmacokinetic Predictions
    Sheila Annie Peters · 2012
45. Interspecies Pharmacokinetic Scaling and the Prediction of Human Pharmacokinetics Using Animal and Cell Models
    Meihua Rose Feng, Nan Zheng, Xinyuan Zhang, Yea Min Huh, Jing‐yu Yu · 2012 · Wiley eBooks
46. Principles, Issues, and Applications of Interspecies Scaling
    Iftekhar Mahmood · 2004 · Drugs and the pharmaceutical sciences
47. Model-informed drug development and discovery: an overview of current practices
    Mohamed A. Elmeliegy, Oliver G. Ghobrial · 2020 · Elsevier eBooks
48. Pharmacokinetic characterization of drugs and new product development
    Bappaditya Chatterjee, Pinaki Sengupta, Rakesh Kumar Tekade · 2021 · Elsevier eBooks
49. Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics
    Donald E. Mager · 2012 · Springer eBooks
50. Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI‐6148 for the Treatment of Cutaneous Leishmaniasis
    Rasmus Hansen Henninger, W. Schouten, Byron Arana, Jean-Yves Gillon, Charles E. Mowbray, J. M. Kratz, K. Van Bocxlaer, T. Dorlo · 2026 · Clinical and Translational Science
51. Pharmacokinetics of Inhibitors of Succinyl-CoA:3-Ketoacid CoA Transferase in Sprague–Dawley Rats, and the Effect of a High-Fat Diet
    Hamdah al-Nebaihi, S. Dakhili, J. Ussher, D. Brocks · 2026 · AAPS Journal
52. Across‐Species Meta‐Analysis of Betamethasone Pharmacokinetics Utilizing a Minimal PBPK Model
    Cong Zhang, W. J. Jusko · 2025 · Biopharmaceutics & drug disposition
53. Prediction of first-in-human dose for new composition bee venom based on allometric scaling and pharmacokinetic modeling approach
    Soon Uk Chae, Jee Sun Min, Seong Jun Jo, Chae Bin Lee, Jinha Park, Soo Hyeon Bae, Soo Kyung Bae · 2025 · Translational and Clinical Pharmacology
54. Exploring New Avenues In Drug Discovery And Development: Insight Into Pharmacokinetics And Pharmacodynamics
    Itishree Prusty · 2024 · Journal of Applied Bioanalysis
55. Applicability of the Øie‐Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase
    Masahiro Yahata, Yuji Ishii, Tetsuya Nakagawa, Takao Watanabe, Izuru Miyawaki · 2020 · Biopharmaceutics & Drug Disposition
56. Noteworthy idiosyncrasies of 1α,25‐dihydroxyvitamin D3 kinetics for extrapolation from mouse to man: Commentary
    Keumhan Noh, Qi Joy Yang, Lavtej Sekhon, Holly P. Quach, Edwin C.Y. Chow, K. Sandy Pang · 2020 · Biopharmaceutics & Drug Disposition
57. Pharmacological vs. classical approaches in the design of first in man clinical drug trials
    Cornelis A. van den Bogert, Adam F. Cohen, Hubert G. M. Leufkens, Joop van Gerven · 2017 · British Journal of Clinical Pharmacology
58. The Most Important Feature of an Organism's Biology
    J. Bertram · 2016
59. Necropsy and Gross Pathology
    C. Spainhour · 2015
60. LC–MS Method for the Quantification of Clonazepam in Rat Plasma
    Ji-Feng Gu, Nian-Zu Chen, Jingchao Yan, Tao-Min Huang, Donglei Wang, Yong-Hua Lai · 2009
61. Preclinical Prediction of Human Pharmacokinetics
    Malcolm Rowland, Robert L. Dedrick · 2012 · Elsevier eBooks
62. Major Principles and Concepts of Risk Assessment
    G. Brambilla, M. Greiner, U. Gundert-Remy, G. Heinemeyer, F. Neisel, W. ter Burg · 2019 · The Practice of Consumer Exposure Assessment
63. PKPD Aspects of Brain Drug Delivery in a Translational Perspective
    E. de Lange · 2014 · AAPS advances in the pharmaceutical sciences series
64. Research and Development of New Radiopharmaceuticals
    G. Holl · 2011
65. The Use of Liver Microsome In -Vitro Methods to Study Toxicant Metabolism and Predict Species Efficacy
    K. Horak, Chad R. Wermager, T. Primus · 2010
66. A Pharmacokinetics and Pharmacodynamics (PK/PD) Guided Approach to Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents
    Nageshwar R. Budha · 2009
67. Allometric Scaling
    Joerg Mayer, Gretchen E. Kaufman, Mark A. Pokras · 2006 · Elsevier eBooks
68. Interspecies Scaling in Blast Pulmonary Trauma
    Garrett W. Wood, M. Panzer, Courtney A. Cox, C. Bass · 2018 · Human Factors and Mechanical Engineering for Defense and Safety
69. Multi-species assessment of propranolol pharmacokinetics via minimal and whole-body PBPK modeling
    Minsoo Lee, Min-Jie Ji, Yoo-seong Jeong, Wooin Lee · 2026 · Frontiers in Pharmacology
70. Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis
    Jose M. Calderin, Sean Wasserman, Rosleine Antilus-Sainte, M. Cristaldo, N. Odjourian, Faye Lanni, F. Kaya, N. Abdelgawad, J. E. Reséndiz-Galván, M. Zimmerman et al. · 2026 · Antimicrobial Agents and Chemotherapy
71. Population pharmacokinetic modeling-based human health risk assessment of di-isodecyl phthalate using biomonitoring-driven reverse dosimetry.
    Ji-Hun Jang, Chen Zhou, Chi-Ho Lee, S. Jeong · 2026 · Journal of Hazardous Materials
72. Tebapivat: Pharmacokinetic Properties in Preclinical Species and Pharmacodynamic Responses Associated With Pyruvate Kinase Activation in Wild‐Type Mice
    Chuck W. Locuson, Sébastien Ronseaux, Michael McVay · 2026 · Biopharmaceutics & Drug Disposition
73. Breaking Barriers Between Species: Integrated Multi‐Species PK Models Improve Human PK Predictions
    Miriam S. R. Happ, Jens Markus Borghardt, Charlotte Kloft, Hermann Rapp, Achim Sauer, Anneke Himstedt, Bettina Gerner · 2026 · CPT Pharmacometrics & Systems Pharmacology
74. PK-PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer
    Se Jin Kim, Robert R. Bies, Donald E. Mager · 2026 · Pharmaceutical Research
75. Model-informed prediction of human pharmacokinetics and first-in-human dose selection of J2H-1702, a novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for metabolic-associated steatohepatitis
    Inkyu Kim, Inyoung Hwang, Sang Won Lee, Yun Kim · 2026 · European Journal of Pharmaceutical Sciences
76. Characterization of small molecule drug clearance mechanisms using in vitro and in vivo approaches in drug discovery and development
    Cindy Yanfei Li, Nashid Farhan, Erickson Mesina Paragas, Hiranmayee Kandala, Upendra P. Dahal · 2025 · Expert Opinion on Drug Metabolism & Toxicology
77. Evaluating the absence of allometric scaling for hepatic microsomal Phase I and Phase II xenobiotic biotransformation among mammals
    Luke Ockhuijsen, Ad M.J. Ragas, A. Jan Hendriks · 2025 · Toxicology
78. Single- and Multiple-dose Pharmacokinetics, Excretion, Metabolism, and Safety of the Antivirulence Agent Fluorothiazinone in Healthy Adults
    M. V. Savitskii, N. E. Moskaleva, S. Appolonova, A. Brito, N. Bondareva, N. L. Lubenec, A. Sheremet, M. K. Ordzhonikidze, N. Zigangirova, S. K. Zyryanov et al. · 2025 · Pharmaceutical Research
79. Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans
    Sohyun Park, Youn Woo Lee, Jaeseong Oh, Su Jin Kim, Sukmook Lee, Ho‐Young Lee · 2022 · Clinical and Translational Science
80. Tylosin Dosage Adjustment Based on Allometric Scaling in Male Turkeys
    B. Poźniak, M. Tikhomirov, K. Bobrek, P. Jajor, M. Świtała · 2021 · Antibiotics
81. Toxicokinetics an essential tool in drug discovery: A review article
    Sandhya · 2021 · IP International Journal of Comprehensive and Advanced Pharmacology
82. Complexus cordis
    H. Ilárraza-Lomelí, M. Rius-Suárez · 2020 · Archivos de Cardiología de México
83. Letter concerning: Clewell (2019) incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene
    Marco Paul Johann Kaltofen, Keeve Edward Nachman, Dale B. Hattis · 2020 · Inhalation Toxicology
84. Prediction of Human Pharmacokinetics and Pharmacodynamics
    Ulf Bredberg · 2018 · Methods and principles in medicinal chemistry
85. The development of a mathematical modelling framework to translate TB vaccine responses between species and predict the most immunogenic dose in humans using animal data
    Sophie J. Rhodes · 2018
86. Human Pharmacokinetics Prediction
    Hardik Chandasana · 2016 · Journal of Drug Metabolism & Toxicology
87. Attrition in Phase I
    Dennis A. Smith, Thomas A. Baillie · 2015 · Wiley eBooks
88. Investigation of the role of pharmacokinetics and the development of novel anti-obesity agents
    I. Christakis · 2015
89. Clinical Dose Estimation Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
    Lingling Guan · 2012
90. Functional Mapping for Predicting Drug Response and Enabling Personalized Medicine
    Yao Li, W. Hou, Wei Zhao, K. Ahn, Rong-Ling Wu · 2011
91. Interrelationship between Pharmacokinetics and Metabolism
    James William Paxton · 2010 · Wiley eBooks
92. Interspecies Pharmacokinetics of Xymedon
    V. I. Pogorel’tsev, S. Garmonov, O. V. Polekhina, V. Reznik · 2005 · Bulletin of experimental biology and medicine
93. Modeling and Simulation in the Translational Pharmacology of CNS Drugs
    E. de Lange, P. Bonate · 2019 · Translational Medicine in CNS Drug Development
94. Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins
    Bernd Meibohm · 2019 · Springer eBooks
95. Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic
    Bianca M. Liederer, Xingrong Liu, Simon G.W. Wong, Daniel R. Mudra · 2017 · AAPS advances in the pharmaceutical sciences series
96. Pharmacokinetics and pharmacodynamics of KR-66223, a novel DPP-4 inhibitor.
    J. Song, Kyeong-Ryoon Lee, Hyun-Jin Kwon, S. Dal Rhee, Min Sun Kim, S. Choi, Sung-Hack Lee, I. Song, J. Ahn, Sung-Hoon Ahn et al. · 2012 · Drug Metabolism and Pharmacokinetics
97. Pharmacokinetics of oxamniquine in rabbit and rat
    Gilbert O. Kokwaro, A. Indalo, Glyn Taylor · 2010 · European journal of drug metabolism and pharmacokinetics
98. Animal Scale-Up
    Robert L. Dedrick, Arthur J. Atkinson · 2007 · Elsevier eBooks